✦ LIBER ✦

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

✍ Scribed by Glück, S.

Book ID: 123092734
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 72 KB
Volume: 19
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(08)80060-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Neoadjuvant Docetaxel,

Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancer

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 70 KB

439 Significantly Higher Pathologic Comp

439 Significantly Higher Pathologic Complete Response Rate with Weekly Compared with Three-weekly Paclitaxel and Carboplatin Plus Trastuzumab Neoadjuvant Therapy – Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer

✍ Z.M. Shao; C.M. Chen; Y. Zhou; S. Chen; Y.F. Hou; G.Y. Liu; G.H. Di; J.S. Lu; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase II Trial of Trastuzumab in Combina

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

✍ Ebb, D.; Meyers, P.; Grier, H.; Bernstein, M.; Gorlick, R.; Lipshultz, S. E.; Kr 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 180 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Brufsky, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 99 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB